CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 395 enrolled
Drug / intervention
Detrusitol 4 mg QD +1 moredrug
Likely dose
Detrusitol 4 mg QDfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01661621
NCT01661621Phase 4Completed
CompareCT.gov

Antimuscarinics as the First-line Treatment for Male With International Prostate Symptom Score (IPSS) Voiding-to-storage Subscore Rati (IPSS-V/S)≤1-- A Prospective Randomized Study Comparing With α-blockers

Buddhist Tzu Chi General Hospital·interventional·Posted Aug 9, 2012·Updated Jun 25, 2014

In Brief

A Phase 4 clinical trial evaluating Detrusitol 4 mg QD and Doxazosin 4 mg QD for Bladder Outlet Obstruction. Completed, enrolled 395 participants across 1 site.

Detailed Summary

This study is a prospective randomized, open label, controlled, double arm, post-marketing study to compare the treatment efficacy of first-line antimuscarinics and α-blockers monotherapy for men with moderate to severe lower urinary tract symptoms (LUTS) (International Prostate Symptom Score (IPSS-T) ≥8) and IPSS voiding-to-storage subscore ratio (IPSS-V/S) ≤1.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Outlet Obstruction
CountriesTaiwan
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 9, 2012
Enrollment StartAug 1, 2012
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 13.9 years ago

Interventions

Detrusitol 4 mg QDdrug

Group 1

Doxazosin 4 mg QDdrug

Group 2